Drug profile · INN
potassium aminosalicylate
PASKALIUM
potassium aminosalicylate (PASKALIUM) is a dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — potassium aminosalicylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
potassium aminosalicylate (PASKALIUM) is a dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydrofolate reductase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is potassium aminosalicylate?
potassium aminosalicylate (PASKALIUM) is a dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for potassium aminosalicylate?
PASKALIUM is a marketed brand name for potassium aminosalicylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of potassium aminosalicylate?
potassium aminosalicylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.